Beyond heparin and aspirin: New treatments for unstable angina and non- Q-wave myocardial infarction

Archives of Internal Medicine

Volumn 160, Issue 6, 2002, Pages 749-758

  Weitz, Jeffrey I ^{a,b,c,d,e,f,g}   Bates, Shannon M ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

^c Medicines Company   (United States)

^d SANOFI   (France)

^e Rhone Poulence Rorer   (United States)

^f PFIZER INC   (United States)

^g MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN DERIVATIVE; HIRUDIN; HIRULOG; PYRIDINE DERIVATIVE; THROMBIN INHIBITOR; TICLOPIDINE;

DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HEART INFARCTION; HEART MUSCLE PERFUSION; HUMAN; PRIORITY JOURNAL; REVIEW; UNSTABLE ANGINA PECTORIS;

EID: 0343238851     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.6.749     Document Type: Review

References (67)

1. Giri S, Waters DD. Pathophysiology and initial management of the acute coronary syndromes. Curr Opin Cardiol. 1996;11:351-360.
2. Fuster V. Elucidation of the role of plaque instability and rupture in acute coronary events. Am J Cardiol. 1995;76(suppl C):24C-33C.
3. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology (Lewis A. Conner Memorial Lecture). Circulation. 1994;90:2126-2146.
4. Fuster V, Stein B, Ambrose JA, et al. Atherosclerotic plaque rupture and thrombosis: evolving concepts. Circulation. 1990;82(suppl II):II-47-II-59.
5. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
6. Stein B, Fuster V, Halperin JL, Chesebro JH. Antithrombotic therapy in cardiac disease: an emerging approach based on pathogenesis and risk. Circulation. 1989;80:1502-1513.
7. Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation. 1990;82(suppl):II-38-II-46.
8. Mizuno K, Satomura K, Miyamoto A, Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med. 1992; 326:287-291.
9. Landau C, Lange RA, Hillis LD. Percutaneous transluminal coronary angioplasty. N Engl J Med. 1994; 330:981-993.
10. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA. 1996;276: 811-815.
11. Patrono C, Renda G. Platelet activation and inhibition in unstable coronary syndromes. Am J Cardiol. 1997;80(suppl 5A):17E-20E.
12. Ridker PM, Manson JE, Gaziano JM, Buring JE, Hennekens CH. Low-dose aspirin therapy for chronic stable angina: a randomized, placebo-controlled clinical trial. Ann Intern Med. 1991: 114:835-839.
13. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
14. Willard JE, Lange RA, Hillis LD. The use of aspirin in ischemic heart disease. N Engl J Med. 1992; 327:175-181.
15. Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost. 1992;67:639-643.
16. Eisenberg PR, Siegel JE, Abendschein DR, et al. Importance of factor Xa in determining the procoagulant activity of whole blood clots. J Clin Invest. 1993;91:1877-1883.
17. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin-III independent inhibitors. J Clin Invest. 1990;86:385-391.
18. Kumar R, Beguin S, Hemker HC. The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity. Thromb Haemost. 1995;74:962-968.
19. Kumar R, Beguin S, Hemker HC. The influence of fibrinogen and fibrin on thrombin generation evidence for feedback activation of the clotting system by clot-bound thrombin. Thromb Haemost 1994;72:713-721.
20. Cattaneo M, Akkawat B, Lecchi A, et al. Ticlopidine selectively inhibits human platelet responses to adenosine diphosphate. Thromb Haemost. 1991;66:694-699.
21. Coukell AJ, Markham A. Clopidogrel. Drugs. 1997; 54:745-750.
22. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308: 81-106.
23. Gent M. A systematic overview of randomized trials of antiplatelet agents for the prevention of stroke, myocardial infarction, and vascular death. In: Mass WK, Easton JD, eds. Ticlopidine, Platelets and Vascular Disease. New York, NY: Springer-Verlag NY Inc: 1993:99-116.
24. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348:1329-1339.
25. White HD. Unmet therapeutic needs in the management of acute ischemia. Am J Cardiol. 1997; 80(suppl 4A):2B-10B.
26. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med. 1996;334:1084-1089.
27. Weitz JI, Hirsh J. New antithrombotic agents. Chest. 1998;114(suppl):715S-727S.
28. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoprotein IIb and/or IIIa. J Clin Invesf. 1983;72:325-338.
29. Coller BS, Anderson K, Weisman HF. New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb Haemost. 1995;74:302-308.
30. 3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surg. 1994;19:125-134.
31. Simoons ML, de Boer MJ, van den Brand MJBM, et al, for the European Cooperative Study Group. Randomized trial of aGPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation. 1994;89:596-603.
32. Fergusson JJ, Kereiakes DJ, Adgey AAJ, et al. Safe use of platelet GPIIb/IIIa inhibitors. Eur Heart J. 1998;19(suppl D):D40-D51.
33. Tcheng JE, Ellis SG, George BS, et al.Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 1994;90:1757-1764.
34. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GPIIb/IIIa receptor blockade. Circulation. 1998;97:1680-1688.
35. Rosenberg RD, Bauer KA. The heparin-antithrombin system: a natural anticoagulant mechanism. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd ed. Philadelphia, Pa: Lippincott William & Wilkins; 1994: 837-860.
36. Ofosu FA, Barrowclifte TW. Mechanisms of action of low-molecular-weight heparins and heparinoids. Baillieres Clin Haematol, 1990;3:505-529.
37. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337:688-698.
38. Cadroy Y, Pourrat J, Baladre MF, et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res. 1991;63:385-390.
39. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-moelcular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
40. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to Coumadin. Thromb Haemost. 1994:71:7-11.
41. Fox I, Dawson A. Loyonds P, et al. Anticoagulant activity of Hirulog, a direct tnrombin inhibitor, in humans. Thromb Haemost. 1993;69:157-163.
42. Stone SR, Maraganore JM. Hirudin interactions with thrombin. In: Berliner LJ. ed. Thrombin:Structure and Function. New York, NY: Plenum Publishing Corp; 1992:219-252.
43. Cannon CP, Braunwald E. Hirudin: initial results in acute myocardial infarction, unstable angina and angioplasty. J Am Coll Cardiol. 1995;25(suppl): 305-325.
44. Lefkoutis J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation. 1994;90: 1522-1536.
45. CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-1435.
46. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary artery syndromes N Engl J Med. 1998;388:436-442.
47. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338:1498-1505.
48. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338:1488-1497.
49. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low-molecular-weight heparin versus regular heparin or aspirin in the treatment of unstable angina. J Am Coll Cardiol. 1994;24:39-45.
50. Fragmin During Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet. 1996;347:561-568.
51. Swahn E, Wallentin L, for the FRISC Study Group. Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). Am J Cardiol. 1997;80(Suppl 5A):25E-29E.
52. Klein W, Buchwald A, Hillis SE, et al, for the FRIC Investigators. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation. 1997;96:61-68.
53. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997;337:447-452.
54. Goodman S, Bigonzi F, Radley D, Le Louer V, Gosset F, Cohen M, for the ESSENCE Group, One-year follow-up of the ESSENCE trial (enoxaparin versus heparin in unstable angina and non-Q-wave myocardial infarction [abstract], Eur Heart J. 1998;50. Abstract P477.
55. Antman EM, McCabe CH, Gurfinkel EP, et al, for the TIMI 11B Investigators. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation. 1999;100:1593-1601.
56. Topol EJ, Fuster V, Harrington DJ, et al. Recombinant hirudin for unstable angina pectoris: a multicentre, randomized, angiographic trial. Circulation. 1994;89:1557-1559.
57. GUSTO IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 1996; 335:775-782.
58. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Circulation. 1997;96:769-777.
59. OASIS-2 Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infraction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet. 1999;353:429-438.
60. Fuchs J, Cannon CP, and the TIMI 7 Investigators. Hirulog in the treatment of unstable angina: results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 Trial. Circulation. 1995;92:727-733.
61. Lindon R-M, Theroux P, Juneau M, et al. Initial experience with a direct antithrombin, hirulog, in unstable angina: anticoagulant, antithrombotic, and clinical effects. Circulation. 1993;88(pt 1):1495-1501.
62. Sharma GVRK, Lapsley D, Vita JA, et al. Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris. Am J Cardiol 1993;18:1357-1360.
63. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med. 1995;333:764-769.
64. Kong DF, Topol EJ, Bittl JA, et al. Clinical outcomes of bivalirudin for acute coronary syndromes. Circulation. 1999;100:2049-2053.
65. Woltzt M, Weltermann A, Nieszpaur-Los M, et al. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man. Thromb Haemost. 1995; 73:439-443.
66. Van Ryn-McKenna J, Cai L, Ofosu FA, Hirsh J, Buchanan MR. Neutralization of enoxaparin-induced bleeding by protamine sulfate. Thromb Haemost. 1990;63:271-274.
67. Mark DB, Cowper PA, Berkowitz SO, et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Circulation. 1998; 97:1702-1707.